AUS
NZ
UK
CA
USA
IND
Healthcare
Percheron Therapeutics (ASX:PER) Advances Partnership Talks Amid Strategic Growth Plans
February 12, 2025 12:46 PM AEDT| By Team Kalkine MediaHighlights,Percheron Therapeutics (,ASX:PER,) expects partnership proposals for its phase IIb trial by the end of February.,The company explores new clinical candidates after the ATL1102 study outcome.,Broader strategic partnerships are being conside...
Healthcare leaders in the ASX sector juggle multiple roles within this interconnected industry.
February 12, 2025 11:00 AM AEDT| By Team Kalkine MediaHighlights,ASX healthcare sector leaders frequently engage with multiple companies, providing strategic insight and fostering growth.,Executives like Syntara's Gary Phillips and Dimerix's Dr Nina Webster play pivotal roles in advancing early-stage dr...
Vitura Health Acquires Telehealth Platform for Medical Cannabis
February 12, 2025 11:00 AM AEDT| By Team Kalkine MediaHighlights,Vitura Health (ASX:VIT) expands its telehealth portfolio by acquiring Candor Medical for $5.9 million.,CSL (ASX:CSL) experiences mixed reactions to its recent financial results, with varying expert opinions.,Percheron Therapeutics (ASX:PER...
Dr. Boreham’s Crucible: Why is Biotech Giant CSL Creating Such a Stir?
February 12, 2025 11:00 AM AEDT| By Team Kalkine MediaCSL Faces Challenges and Opportunities in Flu Vaccine Market Amidst Diverging Divisional Performance
Island finishes dosing in the Phase 2b segment of its dengue trial, spread by mosquitoes.
February 12, 2025 11:00 AM AEDT| By Team Kalkine MediaHighlights:,Island Pharmaceuticals (ILA) successfully completes Phase 2b trial dosing for ISLA-101, focused on dengue fever treatment.,Results anticipated in the coming weeks, evaluating the drug’s effectiveness in reducing viral levels and symptoms....
Ansell Limited Mastering Debt Management and Financial Resilience in the Medical Equipment Sector
February 11, 2025 07:31 PM AEDT| By Team Kalkine MediaAnsell Limited Mastering Debt Management and Financial Resilience in the Medical Equipment Sector
CSL (ASX:CSL) Shares Fall After Underperforming First-Half Results Amid Vaccine Business Struggles
February 11, 2025 03:41 PM AEDT| By Team Kalkine MediaHighlights,CSL (CSL) misses first-half estimates.,Seqirus vaccine division,impacted,by low influenza,immunisation,rates.,Full-year revenue and NPATA guidance remain unchanged despite,results,.,Shares of CSL (ASX:CSL) experienced a dramatic reversal i...
Botanix Pharmaceuticals (ASX:BOT) Charting the Road to Operational Stability
February 11, 2025 03:32 PM AEDT| By Team Kalkine MediaBotanix Pharmaceuticals (ASX:BOT) Charting the Road to Operational Stability
Ramsay Health Care Shares Surge 4.6% on Tuesday. Here's Why.
February 11, 2025 11:23 AM AEDT| By Team Kalkine MediaHighlights,Ramsay Health Care shares jumped,4.6% to AU$35.81,, their highest level since December 2023.,The company forecasts,1H25 underlying NPAT of AU$150M–AU$160M,, exceeding analyst expectations.,Ramsay flagged a,AU$305M impairment,for its UK seg...
CSL Shares Edge Higher on Half-Year Results, Targets 10-13% NPATA Growth
February 11, 2025 11:19 AM AEDT| By Team Kalkine MediaHighlights,CSL shares rose 0.5% to AU$271.68 following the release of its half-year FY25 results.,Revenue grew 5% to US$8.48 billion, while net profit after tax (NPAT) increased 7% in constant currency.,Despite missing consensus estimates, CSL reaffi...
Citi Raises Ansell Price Target Amid Earnings Update and Upgraded Guidance
February 11, 2025 11:12 AM AEDT| By Team Kalkine MediaHighlights,Citi increased its price target for Ansell to AU$38, up from AU$32.50.,Ansell’s 1H25 adjusted EPS of 55.7 US cents beat consensus estimates by 9%.,The company upgraded its FY25 EPS forecast and expects further earnings growth from acquisit...
CSL’s Plasma Strength, Alcidion’s UK Growth, and Cann Group’s Expansion: Key Market Insights
February 11, 2025 11:00 AM AEDT| By Team Kalkine MediaHighlights,CSL’s (ASX:CSL) Plasma Business Drives Growth,– Strong demand for immunoglobulin products offsets flu vaccine challenges, boosting net profit by 7% to US$1.9 billion.,Alcidion (ASX:ALC) Expands in UK Healthcare,– Secures a $5.5 million con...
CSL (ASX:CSL) Delivers Resilient HY25 Results Amid Market Challenges
February 11, 2025 10:52 AM AEDT| By Team Kalkine MediaHighlights,Revenue Growth:,5% increase in HY25, reaching,$8.48 billion,at,constant currency (CC).,Profit Expansion:,Underlying net profit rose 5% at CC to $2.11 billion.,Dividend Boost:,Interim dividend jumped 16% to A$2.08 per share.,CSL (ASX:CSL),...
CSL shares increased by 6% due to strong demand for its CSL Behring division.
February 11, 2025 10:30 AM AEDT| By Team Kalkine MediaCSL shares increased by 6% due to strong demand for its CSL Behring division.
Stakeholder Dynamics at Ramsay Health Care (ASX:RHC)
February 11, 2025 09:31 AM AEDT| By Team Kalkine MediaHighlights,Institutions hold a 41% stake in Ramsay Health Care (RHC).,The top seven shareholders control over half of the company.,General public maintains significant influence in company decisions.,Ramsay Health Care Limited (ASX:RHC) has a diverse...
Evaluating Integer's Financial Performance A Closer Look At ROE And Earnings Growth
February 11, 2025 05:33 AM AEDT| By Team Kalkine MediaEvaluating Integer's Financial Performance A Closer Look At ROE And Earnings Growth
Mayne Pharma (ASX:MYX) Shares Surge on Strong Forecast for 275% Revenue Growth
February 10, 2025 01:41 PM AEDT| By Team Kalkine MediaHighlights,Mayne Pharma (,ASX:MYX,) shares jump 20.5% on positive forecast,Forecasted earnings before interest, tax, depreciation, and amortization (EBITDA) to increase by up to 300%,Revenue set to exceed $210 million, showing strong year-over-year g...
Ansell Shares Surge to Three-Year High on Strong Earnings Outlook
February 10, 2025 01:29 PM AEDT| By Team Kalkine MediaHighlights,Ansell shares hit a three-year high, jumping 6.7% to AU$37.26.,Company raises FY25 earnings guidance, beating analyst expectations.,First-half FY25 sales reach $1.02 billion, up 12.5% year-over-year.,Shares of,Ansell Ltd (ASX:ANN),soared,6...
Mayne Pharma (ASX: MYX) Forecasts Strong 1H25 Revenue Growth with Robust EBITDA Surge
February 10, 2025 12:59 PM AEDT| By Team Kalkine MediaHighlights,Mayne Pharma expects up to $215 million in revenue for 1H25.,Projected EBITDA increase of,nearly 300%,year-on-year.,Focus on Women’s Health and Dermatology driving growth.,Mayne Pharma (ASX: MYX) is forecasting strong financial performance...
Evaluating Cochlear Limited's Stock Valuation A Comprehensive Analysis
February 09, 2025 03:31 PM AEDT| By Team Kalkine MediaEvaluating Cochlear Limited's Stock Valuation A Comprehensive Analysis
Advertise your brand on Kalkine Media